Cell-penetrating peptides successfully delivered siRNA to silence the LDHC gene in triple-negative breast cancer, suppressing tumor growth in zebrafish models with a favorable safety profile.
129-168 nm nanocomplexesCPP:siRNA complexes formed uniform, cell-penetrating particles that successfully delivered gene-silencing therapy to breast cancer cells
What the researchers found
Four cell-penetrating peptides (R10, 10R-RGD, cRGD-10R, and iRGD-10R) were tested for delivering siRNA to silence LDHC in triple-negative breast cancer cells. Key results:
- All CPP:siRNA complexes formed uniform nanocomplexes of 129-168 nm with low polydispersity
- CPP-mediated siRNA delivery successfully silenced LDHC expression in TNBC cells
- LDHC silencing inhibited tumor growth in zebrafish xenograft models
- The approach showed a favorable safety profile with no significant toxicity
- LDHC silencing also enhanced sensitivity to olaparib, a DNA damage response drug, in clonogenic assays
This represents the first proof-of-concept for CPP-mediated LDHC targeting as a cancer therapy strategy.
Why it matters
Triple-negative breast cancer has the fewest treatment options of any breast cancer subtype. LDHC is a particularly attractive target because it is almost exclusively expressed in tumor cells — not in normal tissues — which should minimize side effects. Cell-penetrating peptides offer a drug delivery solution for targets like LDHC where no small-molecule inhibitors exist. This combination of precise target and peptide-based delivery could open new therapeutic avenues for TNBC.
How the study worked
The researchers synthesized four CPP:siRNA nanocomplexes and characterized their physicochemical properties (size, uniformity). They tested delivery efficiency and gene-silencing activity in TNBC cell lines in vitro. Clonogenic assays assessed whether LDHC silencing improved sensitivity to olaparib. In vivo anti-tumor activity was evaluated using a TNBC zebrafish xenograft model, which allows rapid assessment of tumor growth and treatment safety.
What this study cannot tell us
The in vivo testing was limited to zebrafish xenograft models, which are useful for rapid screening but don't fully replicate human tumor biology or drug metabolism. The abstract appears to have incomplete data (truncated results section). No mammalian in vivo models were used, and human clinical translation would require extensive additional testing. The long-term stability and efficacy of CPP:siRNA complexes in more complex biological environments remain unknown.
How to read the evidence
This is a preclinical proof-of-concept study using cell lines and zebrafish xenograft models. While the results are promising and the approach is novel, the evidence is at an early stage. No mammalian in vivo data or human studies are included. The findings demonstrate feasibility but require significant further validation.
When this study was published
Published in 2026, this is a very recent study representing the cutting edge of CPP-mediated cancer therapy research. The field of peptide-based drug delivery is rapidly evolving.
The bigger picture
Cell-penetrating peptides are emerging as a versatile platform for delivering therapeutic molecules that can't reach their targets on their own. This study demonstrates their potential in cancer therapy by combining CPPs with gene-silencing technology (siRNA) to target a tumor-specific gene. As peptide delivery technology advances, this approach could be applied to many other cancer targets where traditional drugs have failed.
Questions still open
- Will CPP-mediated LDHC silencing show efficacy in mammalian tumor models with a complete immune system and more realistic tumor microenvironment?
- Can this CPP delivery approach be optimized for systemic administration in humans, or is it limited to local delivery?
- Would combining CPP-delivered LDHC silencing with olaparib in vivo produce synergistic tumor regression?
Common questions
What are cell-penetrating peptides?
Why is LDHC a good cancer target?
Read the original research
Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model.
Pharmaceutics, 18(1)
Citation
Qasem, Hanan; Naik, Adviti; Gomez, Tricia; Ponraj, Janarthanan; Jafar, Umar; Sikhondze, Martin; Thomas, Remy; Mahmoud, Khaled A; Decock, Julie. (2026). Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model.. Pharmaceutics, 18(1). https://doi.org/10.3390/pharmaceutics18010078